on the vaccine this week, said the highest reporting rate of clot issues — about one case per 100,000 doses administered — has been in women 30 to 49 years old.
A comprehensive review of the blood clot condition following vaccinations between last December and Aug. 31 found six deaths among 50 confirmed cases of the blood clot condition among recipients of the one-shot regimen. During that period, 14 million doses of the vaccine were given, according to theLeana S. Wen, a visiting professor of health policy and management at George Washington University, addresses the rare side effects associated with the vaccine.
Another option, according to a federal official familiar with the situation, would be to recommend the Pfizer-BioNTech and Moderna vaccines over the Johnson & Johnson product, making what is known as a preferential recommendation. Any changes in the vaccine’s use would likely apply to both the initial single shots and boosters, said a second clinician knowledgeable about Thursday’s meeting.Such a recommendation would have to be endorsed by CDC Director Rochelle Walensky to become an official recommendation of the agency.
Regulators believe the benefits of the vaccine outweigh its risks, according to the FDA’s updated fact sheet. At its discussion in April just before lifting the pause, the CDC’s vaccine advisory panel took the same position, but there was debate about whether to add additional warnings targeted to women under 50. That was not done, although the